Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 153,239

Document Document Title
WO/2018/010674A1
Provided are an organic selenium compound, a preparation method thereof, a pharmaceutical composition comprising the same, and a use thereof. The organic selenium compound has a structure represented by formula (I): Ar1-A-C(M)-Se-Ar 2 (I...  
WO/2018/010202A1
A targeted delivery system for a hydrophobic antitumor drug, referring to conjugates of E-selectin polypeptide ligand-polyethylene glycol-antitumor drug connected by different link bridges and containing disulfide bonds. The synthesis of...  
WO/2018/011569A1
The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compound...  
WO/2018/011351A2
The present invention refers to inhibitors of native, non-mutated KRAS for use in preventing and/or treating malignant melanoma and/or hepatocellular carcinoma. In addition, a KRAS inhibitor is combined with an inhibitor of another facto...  
WO/2018/013597A1
The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.  
WO/2018/009972A1
An isolated T cell that is modified to express: a. at least one functional exogenous non-T cell receptor (TCR) that comprises a chimeric antigen receptor (CAR) comprising an antigen binding domain attached to at least one signalling doma...  
WO/2018/011093A1
The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal...  
WO/2018/010053A1
A method for preparing an antitumor drug, comprising the following steps: (1) adding a polymer tetrazole derivative and a crosslinking agent containing methacrylate group to water or a buffer to obtain a carrier solution having a concent...  
WO/2018/011414A1
Derivatives of 1,2,4-Triazolo-[3,4-b]-1,3,4-thiadiazoles according to formula (I), processes for their production, pharmaceutical compositions containing them and their use in the treatment of cancer.  
WO/2018/012994A1
The invention relates to medicinal microbiology and pharmacology, and relates to a preparation exhibiting an immunostimulatory effect, which may be used for the prevention and treatment of oncological diseases. The essence of the inventi...  
WO/2018/012570A1
The purpose of the present invention is to provide a vaccinia virus which expresses a foreign gene and is capable of killing cancer cells, and a medicine for cancer treatment which comprises the vaccinia virus. The present invention rela...  
WO/2018/013867A1
The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and ...  
WO/2018/010514A1
The present invention relates to a heterocyclic compound, a pharmaceutical composition containing the heterocyclic compound, a preparation method therefor, and use thereof as a fibroblast growth factor receptor (FGFR) inhibitor. The comp...  
WO/2018/011138A1
Compound of formula (I´) or (I´´) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders a...  
WO/2018/010142A1
Disclosed are compounds inhibiting the conversion of α–KG to D-2-HG, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmac...  
WO/2018/011265A1
The invention relates to compounds of Formula (I), wherein X, R1A, R1B and R2 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of...  
WO/2018/010624A1
A reversibly cross-linked biodegradable polymer vesicle with a positively charged internal membrane, and a preparation method and application for preparing an anti-tumor drug thereof. A tumor-targeting, reduction-sensitive reversibly cro...  
WO/2018/011227A1
The invention relates to a compound of Formula I : Formula I, or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of tryptophan 2...  
WO/2018/011416A1
The invention relates to a uronic acid monomer for use in a method for treating Alzheimer's disease, cancer, disorders caused by oxidative stress, a viral disease, migraine, or diabetes, wherein the uronic acid monomer is β-D-mannuronic...  
WO/2018/013797A1
Embodiments herein described provide antigen-presenting cell-mimetic scaffolds (APC-MS) and use of such scaffolds to manipulating T-cells. More specifically, the scaffolds are useful for promoting growth, division, differentiation, expan...  
WO/2018/010516A1
A method for modulating a methylation/demethylation state of a nucleic acid, more specifically, a method for site-removing one or more methylated bases from a genome guided by a sgRNA sequence in a cell.  
WO/2018/013486A1
The present invention provides compounds of the formula below (I'): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.  
WO/2018/011376A1
A subject of the present invention is a compound having the general formula (I) a pharmaceutically acceptable salt thereof or a tautomeric form thereof, wherein A, B3, B4, B5, Y, X, B1 and B2 are as defined in any one of claims 1 to 10. ...  
WO/2018/013239A1
This disclosure provides combination therapies for treating cancers. In particular, this disclosure provides methods for treating non-Hodgkin lymphoma comprising administering a combination of a SYK inhibitor and a second therapeutic agent.  
WO/2018/012441A1
Provided are an anticancer agent, radiosensitizer, and food composition capable of heightening the effects of radiation therapy. The present inventors discovered that tumors shrink significantly in comparison to an untreated group and th...  
WO/2018/011806A1
Provided are uses of a therapeutically effective amount of citrulline for the manufacture of a medicament for treatment of a subject having an inflammatory bowel disease (IBD) and/or colon cancer. Also provided are pharmaceutical composi...  
WO/2018/011823A1
Disclosed are compounds and methods for the preparation of Edoxaban. In particular, a camphor sulfonate salt of an amine-protected [(1R,2S,5S)-1,2-amino-5-[(dimethylamino)carbonyl] cyclohexane, an intermediate that may be formed in the s...  
WO/2018/011570A1
The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compound...  
WO/2018/013929A1
Provided herein are compositions and methods for improving immune system function. In particular, provided herein are compositions, methods, and uses of YY1 and EZH2 inhibitors for preventing and reversing T-cell exhaustion (e.g., for us...  
WO/2018/009527A1
The disclosure provides a process of designing and optimizing supramolecular therapeutics. The disclosure also provides a method for designing and optimizing antibody drug conjugates.  
WO/2018/009539A1
Provided herein are substituted substituted heterocycles useful as inhibitors of the HKII enzyme. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention further provides medical uses o...  
WO/2018/009735A1
Solid state forms of Palbociclib dimesylate, processes for preparation thereof and use thereof for preparation of Palbociclib are disclosed.  
WO/2018/007957A1
The present invention refers to novel thiazolo[5,4-d]pyrimidine derivatives that are inverse agonists of the adenosine A2A receptor, to a process for their preparation, to the pharmaceutical compositions containing them and to their use ...  
WO/2018/006795A1
Disclosed are an aromatic acetylene or aromatic ethylene compound, an intermediate, a preparation method, a pharmaceutical composition and a use thereof. The aromatic acetylene or aromatic ethylene compound has a significant inhibitory e...  
WO/2018/009638A1
Multifunctional inhibitors of mTOR, MEK, and PI3K and compositions containing the same are disclosed. Methods of using the multifunctional inhibitors in the treatment of diseases and conditions wherein inhibition of one or more of mTOR, ...  
WO/2018/006804A1
Provided are an application of a compound represented by formula I as a ligand of an orphan nuclear receptor Nur77, and an application for preventing or treating a disease related to the orphan nuclear receptor Nur77.  
WO/2018/008761A1
Disclosed is a novel therapeutic agent for solid cancer, which can harden the whole body of a cell tissue of solid cancer to kill cancer cells or inhibit the proliferation of cancer cells and therefore can solidify the cancer cells. The ...  
WO/2018/007554A1
The present invention relates to a pharmaceutical combination comprising: (a) vinflunine or a pharmaceutically acceptable salt thereof, and (b) at least one PD1 -inhibitor and/or at least one PD-L1 -inhibitor or pharmaceutically acceptab...  
WO/2018/006881A1
A recombinant receptor and an application thereof. The recombinant receptor comprises: a cellular immune-checkpoint molecular segment; an immune stimulator molecular segment; and a T-cell receptor zeta chain.  
WO/2018/007801A1
The present disclosure relates to quantum dot nanoparticles useful for targeting and manipulating mitochondrial function, and to methods of targeting and manipulating mitochondrial function using such quantum dot nanoparticles.  
WO/2018/006882A1
Provided in the present invention is an antibody for anti-claudin 18A2 and an immune effector cell targeting claudin 18A2. Also provided are methods for inducing cell death and treating tumours.  
WO/2018/007556A1
This invention relates to pharmaceutical solid dispersion formulations of Compound A : (I) and the use of theses formulations for treating cancer.  
WO/2018/007592A1
An antibody-drug conjugate (ADC) based on an antibody binding to human AXL and pharmaceutical compositions comprising the ADC for use in the treatment of a cancer comprising administering to a subject a weekly dose of from about 0.45 mg/...  
WO/2018/009417A1
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to macrocyclic α-keto amide derivatives and their use as therapeutic agents.  
WO/2018/006785A1
Provided are an EGFR antibody-cytotoxic drug conjugate, or a pharmaceutically acceptable salt or solvent compound thereof, a pharmaceutical composition comprising the conjugate or the pharmaceutically acceptable salt or solvent compound ...  
WO/2018/006171A1
Methods for identifying a subject with a cancer eligible for treatment with an inhibitor of a Table 1 molecule, optionally a SRC kinase inhibitor or a MET kinase inhibitor, are provided. The methods comprise testing a biological sample f...  
WO/2018/006756A1
A chiral heterocyclic compound with hedgehog pathway antagonist activity, method and use thereof are provided. The chiral heterocyclic compound with hedgehog pathway antagonist activity has the structure represented by formula I. A pharm...  
WO/2018/009544A1
The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK...  
WO/2018/009534A1
The presently disclosed subject matter provides compositions and methods comprising improvements of a CRISPR system (e.g. CRISPR associated (Cas) 9 (CRISPR-Cas9, non-Cas9 CRISPR systems). Such compositions may comprise modifications to t...  
WO/2018/006689A1
The present invention provides use of fulvestrant in the preparation of a medicament for treating nonfunctioning pituitary adenoma. The present invention can effectively improve the prognosis of nonfunctioning pituitary adenoma by means ...  

Matches 1 - 50 out of 153,239